Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
Recent research
Epigenetic regulation of immunity and inflammation has now attracted a lot of attention. The discovery of histone H3K27me3 demethylase, lysine demethylase 6A (KDM6A) (UTX) and 6B (JMJD3) increases our understanding of how methylation kinetics are regulated. Preliminary studies have found that KDM6A is localized to the transcription initiation site of the Hox gene, in which knockdown of KDM6A in zebrafish leads to misregulation of Hox genes and post-developmental defects.
KDM6A contains 29 exons and is one of the X chromosome genes, most of which escape X inactivation. Since both KMT2D and KDM6A are histone modification factors, other pathogenic genes of KS may have functions associated with these two genes. KMT2D and KDM6A have been proposed to counteract the epigenetic control of transcriptionally active chromatin by counteracting the combination of Polycomb histones.
Functional studies have shown that homozygous mutations in KDM6A in mice result in severe midgestational defects, delayed development, neural tube closure, yolk bags and heart defects. In addition, KDM6A-deficient embryonic stem cells showed failure of the cardiac differentiation program. KDM6A was also found to be involved in the mixed lineage leukemia histone methyltransferase and trithorax histones involved in gene activation.
In 2016, a study using genome-wide analysis to compare the high and low reproductive populations of Chinese Laoshan dairy goats found that several genes have potential key effects on fertility, including lysine demethylase 6A (KDM6A), androgen receptor (AR) and anti-Muller disease. Among these genes, KDM6A encodes a protein that trimethylates histone H3 and demethylates dimethylated lysine 27, and can affect gametophyte development. Importantly, many studies have confirmed that the KDM6A gene is critical for animal reproduction. In rodents, knockout of the KDM6A gene disrupts the development of primordial germ cells.
Recently, six KMT2D-mutant negative KS patients have been reported to have deletion or nonsense single nucleotide variation in KDM6A (previous UTX) (histone H3 lysine 27 (H3K27)-specific demethylase). The KDM6A transcript is 5.4 Kb and translated into a 154 kDa protein. KDM6A removes the H3K27me3 marker associated with gene silencing. KDM6A binds to KMT2D and several other proteins, including RBBP5, DPY30, WDR5, MATR3, ASH2L, NSD1, PAXIP1, NCOA6 and c16orf53, in complexes involved in the regulation of various downstream gene expression.
The KDM6A gene was identified as the second causative gene of KS, and de novo deletions and point mutations in the KDM6A coding region have been identified in 9-13% of KMT2D-negative KS patients. KDM6A mutations have been widely observed. Phenotypic profiles range from typical KS to milder clinical manifestations. That is, K12 with a deletion shows a typical KS phenotype. Specific manifestations include long cleft palate, short nasal septum and eversion, short stature, abnormal heart, severe mental retardation, repeated infections and Chiari malformations.
Evidence of the association of a given pathway with a PPI (protein-protein interaction) network derived from KDM6A was examined. Some scholars have studied the KDM6A PPI network diagram. The network consists of 74 nodes connected by 453 edges. KDM6A has seven direct neighbors, RBBP5, WDR5, ASH2L, MLL2, PAXIP1, NCOA6 and RBL2. KDM6A contains a tetrapeptide motif that predicts protein-protein interactions and is not only a member of a stable multiprotein complex that demethylates H3K27me3, but also a MLL2 H3K4 methyltransferase complex that promotes genes expression. Its catalytic activity is related to the regulation of the homeobox (HOX) and RB transcription networks. Different protein partners regulate the recruitment of KDM6A to specific chromatin regions to target specific genes. There are three clusters whose nodes are distinguished by different colors in the network. There is a connection between these clusters.
Figure 1. PPI network of KDM6A.
The PPI network from KDM6A presents a panoramic view that helps to understand the role of KDM6A. The results of path identification and network ontology analysis confirm and complement each other. Systematic evaluation of a gene by a network approach is a useful approach. Given that these may be non-specific interactions, the network can only be considered a guide map.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.